LeMaitre Q2 2026 Financial Results

LeMaitre Vascular delivered double-digit growth and record profitability in Q2 2026.

Risk flags

• ●The qualitative attribution of gross margin improvement to 'higher prices, mix shift, and operational efficiencies' lacks numerical breakdown, which limits visibility into the sustainability of these drivers.
• ●Catheter sales declined 11% in the quarter, and the explanation of 'recall-driven overstocking in Q2 2025' is not supported by specific data, raising questions about underlying demand trends in that segment.
• ●While six international warehouse expansions are underway, no details are provided on associated costs, timelines, or expected returns, introducing execution and capital allocation risks.

Bottom line

LeMaitre Vascular’s Q2 2026 release shows robust, realised growth across revenue, margins, and earnings, with record results in several product lines and geographies. The company’s capital allocation—dividend and share repurchase—signals confidence in ongoing cash generation. Most claims are substantiated by detailed numbers, though some qualitative explanations lack supporting data. Execution risks exist around international expansion and the underperforming catheter segment, but these are outweighed by broad-based strength elsewhere. For investors, the most important takeaway is that LeMaitre’s growth and profitability are not just projected—they are already materialising, with near-term guidance pointing to continued momentum.

Announcement summary

(NASDAQ: LMAT) LeMaitre Vascular, Inc. reported Q2 2026 sales of $70.4mm, representing a 10% increase (+10% organic) over Q2 2025. Gross margin for the quarter was 72.1%, up 210 basis points, and operating income reached $20.4mm, a 26% increase, with an operating margin of 29%. Earnings per share (EPS) for Q2 2026 was $0.74, up 23% from the prior year, and cash increased $9.0mm sequentially to $376.2mm. Artegraft sales rose 34% in the quarter, with grafts (+23%), carotid shunts (+18%), and patches (+4%) each posting records, as did EMEA (+18%), APAC (+18%), and the Americas (+5%). The company announced a quarterly dividend of $0.25/share, payable on September 3, 2026, to stockholders of record on August 20, 2026, and authorized a share repurchase program of up to $100.0mm. The company projects Q3 2026 sales of $66.3mm - $68.3mm, Q4 2026 sales of $71.1mm - $73.1mm, and full-year 2026 sales of $274.3mm - $278.3mm, with gross margins around 72.2%-72.6% and EPS guidance of $2.84 - $2.94 for the year.

Disagree with this article?